Abstract: Provided herein are methods to increase the culture density and/or thickness of a cellular biomass in a cultivation infrastructure, to improve the culture of cells in the absence of serum in a cultivation infrastructure, and to promote anchorage-independent growth of a cellular biomass in a cultivation infrastructure. The methods comprise inhibiting the HIPPO signaling pathway, for example, by activating YAP1, activating TAZ, and/or inhibiting MOB1, LATS1 kinase, LATS2 kinase, WW45, MST1 kinase, and/or MST2 kinase in the cellular biomass. In some embodiments, the cellular biomass is harvested from the cultivation infrastructure for the formulation of cell-based food products or ingredients, such as animal meat manufactured from cells in an ex vivo process or for therapeutic applications such as organ or tissue transplantation or grafting.

Abstract: Embodiments are described that relate to methods and systems for growing cells in a hollow fiber bioreactor. In embodiments, the cells may be exposed to a number of growth factors including a combination of recombinant growth factors. In other embodiments, the cells may be grown in co-culture with other cells, e.g., hMSC's. In embodiments, the cells may include CD34+ cells.

Abstract: The present invention provides a composition comprising dendritic cells loaded with hHsp60sp, which dendritic cells are from a subject and have been fixed with paraformaldehyde (PFA). The subject may suffer from an autoimmune disease. Also provided are a method for preparing the composition; recombinant human cells comprising a heterologous gene encoding a fusion protein of HLA-E and hHsp60sp or B7sp, and expressing the fusion protein on the surface of the cells; a method for determining a percentage of maximum inhibition of testing the function of the HLA-E restricted CD8+ Treg cells from a subject, determining whether HLA-E restricted CD8+ Treg cells freshly isolated from a subject are defective, or determining whether defective HLA-E restricted CD8+ Treg cells from a subject are correctable; and a method for correcting defective HLA-E restricted CD8+ Treg cells, treating type 1 diabetes (T1D), or treating multiple sclerosis (MS).

Abstract: A method to obtain a composition comprising an enriched population of functional mesenchymal stem cells for hypothermic transport and local administration of said enriched population of functional mesenchymal stem cells in therapy. Finally also described is the use of said enriched population of functional mesenchymal stem cells, and compositions comprising them, obtained by the described method, in autologous or allogeneic treatment of diseases susceptible to mesenchymal stem cell therapy, either by local or systemic treatments, and more particularly in the treatment of osteoarticular diseases such as degenerative disc disease, osteoarthritis, and bone repair; in lupus erythematosus, graft-versus-host disease, and other autoimmune diseases; in peripheral vascular insufficiency and other cardiovascular diseases.

Abstract: A method for revitalizing mesenchymal stem cells (MSC) maintained in culture by transducing the MSC with vectors encoding a specific gene combination, as well as methods of use of MSC so revitalized in co-culturing hematopoietic stem cells.

Abstract: The present disclosure provides a method of preparing mimicking angiogenic co-spheroids, including: co-cultring a neural related cell and a cultured cell on hyaluronan-grafted chitosan (CS-HA) substrates to form a co-spheroid of neural related cell/cultured cell, and encapsulating the co-spheroid of neural related cell/cultured cell into a hydrogel to form a mimicking angiogenic co-spheroid. The mimicking angiogenic co-spheroid of the present disclosure can be formed by 3D printing model as a 3D mini-neurovascular unit, which is applicated to a high-throughput angiogenesis screening platform.

Abstract: Methods for the efficient isolation and use of pluripotent adipose-derived stem cells (PASCs) are provided. In certain embodiments the methods involve providing an adipose tissue sample from which the stromal vascular fraction is co-cultured with the adipocyte fraction. PASCs can be isolated with a high degree of purification without requiring an additional cell enrichment process (e.g. cell sorting). PASCs and their conditioned media can be used for tissue regeneration within hours of harvesting the adipose tissue, and without requiring cell expansion. PASCs can grow as floating individual cells, as clusters of cells, or attached to surface(s) of the culture vessel. PASCs do not produce teratomas in vivo, nor do they induce immunorejection upon transplantation, and they achieve a high efficiency in grafting. The cells and compositions can be used for cell therapy and to screen new drugs.

Abstract: The current invention provides for methods of promoting differentiation of human pluripotent stem cells into esophageal progenitor cells as well as the cells obtained from the methods, solutions, compositions, and pharmaceutical compositions comprising such cells. The current invention also provides for methods of using the esophageal progenitor cells for treatment and prevention of disease, and kits.

Abstract: Disclosed are methods of preparing thymic organoids according to embodiments of the invention. Also disclosed are methods of preparing thymic emigrant cells in vitro, according to embodiments of the invention. Also disclosed are methods of treating or preventing a condition in a mammal, e g., cancer.

Abstract: By establishing effective methods for shrimp 3D cell culture and passage, the present invention provides a technology of continuous shrimp cell culture intended for the establishment of immortalized shrimp cell lines. The present invention provides a preparation method of matrigel for 3D cell culture of shrimp by optimizing an additive proportion of matrigel. The present invention further provides a technology of separation and 3D cell culture of shrimp haemolymph cells, where shrimp haemolymph cells adhere to and grow on the surface of the matrigel in the form of a single round cell and a cell pellet/cellular spheroid, with survival and growth abilities being superior to 2D culture effects. The above technology is achieved by optimizing a formula of complete medium for shrimp cells, selecting the medium as an anticoagulant and a diluent for shrimp haemolymph cells, selecting a 3D culture method for surface-adhered growth in the matrigel.

Abstract: The present invention provides a co-culture system and method for assessing cellular cholesterol (Choi) efflux and uptake in vitro. The co-culture system mimics in vivo Choi efflux and uptake in the context of mammalian physiology. The methods and systems provided can be used in some embodiments to evaluate the effect of a pharmacological agent on cellular Choi efflux and uptake or for diagnostic purposes.

Abstract: Compositions and methods for producing major ocular cell types, including retinal ganglion cells, photoreceptors, retinal pigmented epithelium and corneal endothelial cells, from human pluripotent stem cells under defined culture conditions are provided.

Abstract: The present invention provides a method for swiftly producing a layered cell sheet that is non-invasively obtained and is utilizable for transplantation, etc., the method including (1) a step of applying a centrifugal force to a first cell sheet on a temperature-responsive culture surface for a predetermined time in a temperature range from a lower critical solution temperature of the temperature-responsive culture surface to 45° C., (2) a step of further placing a second cell sheet on the first cell sheet, and (3) a step of applying a centrifugal force to the first cell sheet and the second cell sheet on the temperature-responsive culture surface for a predetermined time in the temperature range from the lower critical solution temperature to 45° C.; and also provides a layered cell sheet obtained by the method.

Abstract: The present disclosure provides compositions and methods employing stem cell-derived amnion tissue. In some embodiments, compositions (e.g., scaffolds and devices) and methods of generating amnion-like tissues from hPSCs are provided. In some embodiments, uses of such cells for research, compound screening and analysis, and therapeutics are provided.

Abstract: The present application relates to methods and compositions for treating diseased or damaged cardiac tissue comprising regenerative cells harvested from donor cardiac tissue. In one embodiment, regenerative cells are harvested from an allogeneic source and after administration result in increased viability and/or functional improvement of damaged or diseased cardiac tissue.

Abstract: Methods of screening agents in a cardiomyocyte population are provided. The cardiomyocyte population may be differentiated from a dystrophin knockout iPSC line. High-throughput methods of screening agents in a cardiomyocyte population that has been differentiated from a dystrophin knockout iPSC line are also provided. The methods may include determining an effect of the agents on membrane barrier function by using a cell viability assay. Methods of making dystrophin knockout iPSC lines, making dystrophin knockout iPSC derived cardiomyocytes, and modeling dystrophin deficient cardiomyopathy are also provided.

Abstract: Provided herein are compositions and methods for generation of naive human pluripotent stem cells. The method comprises incubation of iPSCs under 5% O2 in a medium comprising 5% glucose, an MEK inhibitor, a GSK3? inhibitor, human leukemia inhibitory factor (LIF), human insulin and Torin 1. The method does not need any other inhibitors or transgene expression. The naive human pluripotent cells can be used to generate a large amount of mature human cells from all three germ layers in host non-human animals.

Abstract: The present invention relates to a biomaterial comprising adipose-derived stem cells (ASCs), a ceramic material and an extracellular matrix. In particular, the biomaterial according the present invention secretes osteoprotegerin (OPG), and comprises insulin-like growth factor (IGF1) and stromal cell-derived factor 1-alpha (SDF-1?). The present invention also relates to methods for producing the biomaterial and uses thereof.

Abstract: The present invention provides methods and combinations for reducing the infarct volume in a tissue of a subject undergoing ischemia or at risk of developing ischemia.

Abstract: Provided are methods for treating or preventing vasculopathy comprising administering to a subject in need thereof , ac composition comprising a mesenchymal stem cell (MSC), or a part of a culture medium that has been in contact with the MSC and comprises one or more components of the MSC, or an exosome derived from the MSC. Pharmaceutical compositions suitable for such treatment is also provided.